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1. I n t r o d u c t i o n  
T h e  p r e s e n t  e r a  o f  r e c o g n i z i n g  t h e  t r a n s p o r t  s y s t e m s  
o f  l y s o s o m e s  b e g a t ,  i n  1982  w i t h  t h e  d e m o n s t r a t i o n  b y  
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Gahl et al. [1] and Jonas et al. [2] that the extraordinar- 
ily high lysosomal cystine accumulation observed in the 
genetic disorder, nephropathic cystinosis, was due to a 
defect in the lysosomal transport of cystine. This dis- 
covery served as a catalyst for the search and charac- 
terization Of ,-J;her lysosomal transport systems such 
that, 9 years later, 16 different lysosomal transport 
systems are now known with probably many others yet 
to be discovered (Fig. 1). These transport systems sup- 
port the primary function of lysosomes as a major 
intracellular site for the degradation of a large variety 
of both endogenous and exogenous macromolecules. 
Many ¢f the carrier proteins provide pathways for the 
release of degradation products from lysosomes while 
others transport substrates into lysosomes to aid pro- 
cesses of macromolecule breakdown. The iysosomal 
transport systems display some properties and sub- 
strate specificities that are similar to carrier-mediated 
routes in other cellular membranes, but significant 
differences are observed as well, permitting these 
transporters to function within the constraints of the 
acidic environment of the lysosome. None of the lyso- 
somal transporters characterized thus far have been 
found to be dependent on Na + and in some cases 
transport activity is especially sensitive to the pH gradi- 
ent and/or  membrane potential existing across the 
lysosomal membrane. Nearly half of the known lysoso- 
real transport systems have been described in just the 
last 2 years, as the techniques for isolating lysosomes 
and kinetic analysis of lysosomal transport activities 
now allow for rapid detection and characterization of 
lysosomal transport activities. The major focus of this 
review will be to describe the characteristics of the 
different lysosomal transport systems with special em- 
phasis on the new transport routes discovered since 
previous reviews on this subject [3-6]. 
11. Isolation of lysosomes and methods of analysis 
I-A. Methyl ester loading technique 
In addition to the techniques commonly used in 
kinetic analysis of transport, several specialized tech- 
niques have played important roles in the study of 
lysosomal transport systems. The first of these is the 
methyl ester loading technique which was initially de- 
scribed by Goldman and Kaplan and later modified by 
Reeves for loading lysosomes with radiolabelled amino 
acids [7-10]. In this technique, the carboxyl group(s) of 
an amino acid are converted to the methyl ester deriva- 
tive by reaction with methanolic HCI. Methyl esters of 
neutral or acidic amino acids have only the a-NH e 
group (pKa approx. 7.5) that can be protonated. When 
intact cells or isolated organelles are incubated with 
amino acid methyl esters in the neutral pH range (pH 
7-8), a significant proportion of the amino acid methyl 
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Fig. 1. Schematic diagram of the currently known lysosomal transport systems. The amoeboid form in which the lysosome depicted is not typical 
of lysosomal morphology but is used for ease of indicating the different lysosomal transport mutes. 
ester exists in an uncharged form, which rapidly crosses 
cellular membranes. Esterase activities within lyso- 
sprees convert the amino acid methyl esters back to the 
parent amino acids. Since the amino acids are charged 
at the intralysosomal pH, these polar molecules are 
now unable to passively diffuse from lysosomes an~ 
instead accumulate, requiring mediation by specific 
transport routes for their release. The high esterase 
activity in lysosomes relative to other cellular or- 
ganelles allows amino acids to be specifically loaded 
into lysosomes even in the presence of other or- 
ganelles. The methyl ester loading technique was ap- 
plied by Gahl et al. [1] to load cystine into lysosomes of 
human leucocytes and show that lysosomal cystine ef- 
flux was greatly impaired in leucocytes from persons 
with nephropathic cystinosis. 
II-B. Lysosomal uptake studies 
Whereas the methyl ester loading technique allows 
one to study factors affecting exodus of amino acids 
from lysosomal preparations, often more quantitative 
information is gathered from lysosomal uptake studies 
which require that lysosomal preparations must be free 
of other organelles. Highly purified lysosomes are gen- 
erally obtained by centrifuging granular fractions on a 
Pereoll density gradient [11-14]. Typically, lysosomes 
are the only organelle detectable in the bottom one- 
third of these gradients (d = 1.07-1.12 g /cm 3) as de- 
termined by analysis of marker enzymes associated 
with, specific cellular organelles [14]. This method hds 
been used in isolating lysosomes from many different 
cell types. The ~integrity of iysosomal preparations is 
usually found to be 80-90% intact as judged by the 
latency of fl-hexosaminidase activity, defined as the 
difference in activity of this lysosomal enzyme in the 
presence or absence of 0.1% triton [1,15]. Uptake of 
substrates by intact lysosomes is terminated rapidly by 
collecting lysosomes on glass fiber filters, washing the 
filters with ice-cold buffer and then counting the filters 
for radioactivity [14]. Alternatively~ isolated lysosomes 
can be separated from unincorporated radioactivity by 
centrifugation through silicone oil [15]. Substrate up- 
take by intact lysosomes is often expressed per unit cf 
latent fl-hexosaminidase activity. 
Membrane vesicles, prepared by lysing and resealing 
purified lysosomes, have become important for charac- 
terizing some lysosomal transport systems [16-19]. For 
instance, lysosomal sulfate transport has been demon- 
strated in uptake studies with vesicles prepared from 
rat liver lysosomes but apparently is not detectable 
using intact rat liver lysosomes [18]. Membrane vesicles 
may be especially useful for studying lysosomal trans- 
port systems which are highly dependent on proton 
gradients and /o r  membrane potential, because of the 
ability to experimentally impose these conditions in a 
353 
direction and magnitude favorable for analysis. In con- 
trast, uptakes performed with isolated, intact lysosomes 
are subject to the pH gradient and membrane potential 
present after .;solation of lysosomes, which may not be 
favorable for observing the desired transport activity. 
Assays using membrane vesicles prepared from rat 
liver lysosomes have used 0.22 /zm filters [18] or gel 
filtration on small Sephadex columns [16] to separate 
vesicles from the uptake incubation medium. Uptakes 
are expressed per milligram of vesicle protein. 
The application of these methods has now allowed 
for characterization of many different lysosomal trans- 
port systems. It must be stressed that many of the 
lysosomal transport systems to be described have been 
studied in only one cell type. The chdracteristics of 
lysosomal transport systems may vary markedly in lyso- 
somes from different cell types, as already found for 
lysosoma! system h [20] and to a lesser degree for the 
lysosomal cystine transporter [21]. 
Although it is apparent that many of the lysosomal 
transport systems must serve primarily for the net 
removal of their substrates from lysosomes, the net flux 
across the lysosomal membrane for most small molecu- 
lar weight compounds at steady state is not known. 
This lack of knowledge with regard to fluxes is largely 
due to the difficulty of accurately measuring the intra- 
lysosomal concentration of metabolites because of the 
heterogeneous nature of isolated lysosomes, their small 
size and their small contribution to the total intra- 
cellular vole:me. Future improvements in analysis will 
allow a better understanding of the degree to which 
different transport systems are concentrative, their net 
direction of transport, their relationship to one another 
in determining the net flux of a given metabolite and 
how the lysosomal pH gradients and any relevant ion 
gradients affect the directionality_ of transport. 
Carrier-mediated translocation of solutes across 
membrane barriers often involves sign,.'ficant structural 
movement and constant reorientation of components 
within the membrane as hydrogen bonds and hy- 
drophobie interactions constantly break and reform. 
The ease with which these interactions can occur within 
the lipid environment of the membrane are highly 
temperature-dependent, with membrane fluidity and 
the nature of the various lipid phases changing appre- 
ciably over the temperature range from 5 to 37 ° C. The 
effect of these physical interactions is reflected by the 
difference in temperature coefficients between simple 
diffusion and carrier-mediated facilitated diffusion. 
Christensen has noted that simple diffusion has a low 
temperature coefficient with a Ql0 nearer 1 than 2, 
whereas higher Ql0 values are observed for carrier- 
mediated translocation of solutes across cellular mem- 
branes, displaying temperature coefficients as high as 
those characteristic of chemical reactions, i.e., two or 
more [22]. Temperature coefficients for the lysosomal 
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TABLE I 
Temperature coefficients (Qw) determined from Arrhenius plots for the lysosomal transport of different substrates 
Lysosomai Cell type Substrate assayed Qio 
transport system 
Phosphate human fibroblast phosphate uptake 1.8 121 
Cobalamin rat liver lysosomal vesicles cobalamin uptake 1.8 130 
System h FRTL-5 tyrosine uptake 1.9 20 
System h FRTL-5 monoiodotyrosine uptake 1.95 53 
Nucleoside human fibroblast adenosine uptake 2.0 15 
Cystine human leucocyte cystine uptake 2.0 25 
Sulfate rat liver lysosomal vesicles sulfate uptake 2.0 18 
System c human fibroblast lysine efflux 2.2 31 
GalNAc/GIcNAc rat liver lysosomes GalNAc, GIcNAc uptake 2.3 82 
Neutral sugar rat liver lysosomes g~ycose and fucose efflux 2.3 86 
Acidic sugar human fibroblast sialic acid efflux 2.4 80 
Cysteine.specific human fibroblast cysteine uptake 3.2 58 
Reference 
passage of different substrates have been determined 
f ~ m  Arrhenius plots in a variety of studies (Table I). 
These Qt0 values range from 1.8 to 3.2 with a mean of 
2.15 and a median of 2.0. 
As an aid for comparing rates of lysosomal exodus 
of various substrates, we have tabulated the half-times 
for iysosomal exodus of various organic solutes which 
have been reported in the literature (Table II). Some 
of the lysosomal transport systems rapidly transport 
their substrates out of lysosomes, displaying half-times 
less than 10 min at 37 ° C. It should be mentioned that 
half-times of exodus reflect the initial velocity only 
when lysosomes are loaded with a substrate below the 
saturation level of the transport route involved. Half- 
times of exodus can be influenced strongly by the level 
of loading when lysosomes are loaded with substrate 
above the saturation level of the transport route. 
II1. Amino acid transport systems 
I l iA.  Lysosomal cystine transport and cystinosis 
The autosomal recessive disease, nephropathic cysti- 
nosis, has been known since 1907 when Abderhalden 
described a family in which three infants had died of 
apparent malnutrition [23]. Autopsy of one of the three 
children demonstrated white crystalline material in the 
liver which was shown to be the amino acid, cystine. 
After initial confusion of this disorder with the unre- 
lated inborn error of metabolism, 'cystinuria', cysti- 
TABLE II 
Half-time of exodus of various organic solutes" from lysosomes 
in each experiment referenced below lysosomes were loaded with the indicated solute and, subsequently, the time required for 50% of the solute 
to egress from lysosomes at the indicated pH and temp was determined. This time interval is referred to as the half-time of exodus. 
















approx, 2 rain at pH 7.0 and 37 ° C in FRTL-5 cells 20 
2-3 min at pH 7.0 and 37 ° C in human fibroblasts 78 
3 rain at pH 7.0 and 25 ° C in rat liver 86 
1-2 min at pH 7.0 and 25 o C in rat liver 86 
5-7 min at pH 7.0 and 37 ° C in human fibroblasts 51 
5 min at pH 7.0 and 37 ° C in human fibroblasts 15 
7.5 min at pH 7.0 and 37 ° C in human fibroblasts 15 
17 rain at pH 7.0 and 37 ° C in human leucocytes 54 
t8 min at pH 7.0 and 37 ° C in human leucocytes 54 
24 rain at pH 6.5 and 25 ° C in human fibroblasts 31 
26 min at pH 7.0 and 37 o C in human leucocytes 54 
26 min at pH 7.0 and 37 ° C in human leucocytes 54 
30 min at pH 7.0 and 37 ° C in human fibroblasts 31 
approx. 45 min at pH 7.0 and 37 ° C in Epstein Barr-transformed human lymphoblasts 28 
39 min at pH 6.5 and 28 ° C in human fibroblasts 
45 min at pH 7.0 and 37 ° C in human leucocytes 20 
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Fig. 2. Velocity of eystine egress from granular fractions isolated 
from leukocytes of normal subjects, cystinotic patients and subjects 
heterozygous for cystinesis. Leuk(,cytes from two normal subjects (e, 
,, ) and two..obligate heterozygotes for cystinosis (0 ,  ,x ) were loaded 
with 0.1 t:, 2.0 mM unlabelled cystine dimethyi ester. Granular 
fractions were prepared and velocities of cystine egress were deter- 
mined at each level of loading. Leukocytes from four different 
cystinosis patients (X I to X 4) were loaded to a single cystine level 
and the velocity of cystine egress from isolated granular fractions was 
determined [11. 
nosis became recognized as the mo~t common underly- 
ing genetic cause of the renal Fanconi syndrome. In 
1967-68, subcellular fractionation and electron micro- 
scopic studies definitively showed that the cystine zccu- 
mulations which occur in this condition are contained 
within lysosomes [24]. 
Cystine, although poorly soluble, occurs as the free 
amino acid in various body fluids. Cystine is also a 
component of many proteins, stabilizing their struc- 
tures through disulfide bridges. When endogenous and 
exogenous proteins which contain disulfides are de- 
graded within lysosomes, the cystine released by this 
hydrolysis is normally transported from lysosomes back 
into the cytosol by a transport system with high speci- 
ficity for cystine. Evidence for this transport route and 
its failure in nephropathic cystinosis, was first provided 
by Gahl et al. and Jonas et al. [1,2]. Gahl et al. applied 
the methyl ester loading technique to load leukocyte 
lysosomes with cystine and demonstrate egress of cys- 
tine from lysosomes in the granular fraction of normal 
ceils, whereas such activity was lacking in lysosomes 
from persons with nephropathic cystinosis (Fig. 2). 
Obligate heterozygotes for nephropathic cystinosis dis- 
played velocities of lysosomal cystine exodus which 
were close to 50% of that of normal individuals [1]. 
Jonas et al. loaded lysosomes with cystine by incubat- 
ing fibroblasts with 30 mM cysteine-glutathione mixed 
disulfide. Intact normal and heterozygous fibroblasts 
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rapidly lost their lysosomal cystine ( t~/2 = 20 min), 
whereas cystinotic fibroblasts showed no loss of cystine 
during a 90 min incuba6on period at 37 °C [2]. Al- 
though cystine loss from lysosomes could be observed 
when lysosomes were present within intact or heterozy- 
gous fibrob!asts by this method, cystine egress could 
not be demonstrated using isolated lysosomes [2]. 
Since this discovery, many other characteristics of 
the lysosomal cystine transport system have been eluci- 
dated in a variety of cell types including human leuco- 
cytes, human lymphoblasts, human fibroblasts, mouse 
fibroblasts, rat liver cells and FRTL-5 cells 
[1,2,20,21,25-33]. This transport route recognizes the 
L-isomer of cystine and selenocystine with the highest 
affinity and weakly recognizes cystathionine, cys- 
teamine-cysteine mixed disulfide and cystamine as indi- 
cated by their ability to moderately inhibit lysosomal 
cystine transport [21,25]. Lysosomal cystine uptake dis- 
plays a pH optimum between pH 5.5 and 6.5 in human 
leucocyte lysosomes [26] and a K m of 0.3-0.5 mM has 
been found for cystine uptake at pH 7.0 and 37 °C by 
lysosomes of human leucocytes and mouse fibroblasts 
[21,25]. The lysosomal cystine transport system exhibits 
a t rans -s t imula t ion  property in human leucocytes, 
FRTL-5 cells and mouse fibroblasts [20,21,25], showing 
much greater uptake of radiolabelled cystine when 
uptakes are performed with lysosomes pre-loaded with 
a high concentration of unlabelled cystine. In addition, 
Gahl et al. [25] have shown that [aSS]cystathionine 
uptake is trans-stimulated 7-fold using leucocyte lyso- 
somes pre-loaded with unlabelled cystine, t rans -S t imu-  
lation of lysosomal cystine transport has not been ob- 
served, however, in human fibroblasts (R. Pisoni, un- 
published data). 
Efflux of cystine from lysosomes occurs with a half- 
time of 25-45 min at 37 °C and pH 7.0 in human 
leucocytes, fibroblasts and lymphoblasts and is stimu- 
lated 2-3-fold by MgATP [1,2,27-32]. Several studies 
have shown that this stimulatory effect of MgATP on 
lysosomal cystine exodus correlates with an increase in 
the transmembrane proton gradient and /o r  a decrease 
in the potential across the lysosomal membrane 
[28,29,32]. In addition, Jonas et al. [33] have found that 
the polyamines, spermidine, putrescine, cadaverine and 
spermine, at a concentration of 2 mM can stimulate 
lysosomal cystine efflux from rat liver lysosomes 1.3- 
2.1-fold. 
Three different forms of cystinosis are known, all of 
which are inherited as autosomal recessive disorders 
[24]. Nephropathic cystinosis is the most severe and is 
observed more often than the other two forms, benign 
and intermediate cystinosis. The molecular basis for 
the differences between these conditions, all of which 
manifest intralysosomal cystine storage, are not known. 
One report suggests that significant residual lysosomal 
transport activity (9-29%) remains in the benign form, 
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but no significant lysosomal transport of cystine was 
seen in fibroblasts from an intermediate type [34]. 
Complementation analysis by somatic cell hybridization 
between the nephropathic and benign types, or be- 
tween the nephropathic and intermediate types, showed 
no complementation with either cross [35]. These re- 
sults suggest that all three forms of eystinosis are allelic 
mutations. 
There is some indication that an alternative pathway 
may exist in lysosomes which acts as a minor route for 
the release of eystine from lysosomes. Lemons et al. 
[36] found that eystine was lost at a substantially accel- 
erated rate from lysosomes of cystinotic cells when 
exposed to elevated temperatures of 40 or 43 ° C. This 
temperature effect was observed in five different 
cystinotic cell lines from unrelated families including 
nephropathic, intermediate and benign forms of cysti- 
nosis. In contrast, exodus of cystathionine from lyso- 
somes was the same at 37 °C or 43 °C indicating that 
this effect of temperature was not a general phe- 
nomenon affecting lysosomal permeability. It was spec- 
ulated that lysosomal cystine loss at elevated tempera- 
tures was due to a transport route different from that 
which is defective in eystinosis, with the alternate path- 
way significantly contributing to lysosomal cystine exo- 
dus only at elevated temperatures. Recently, Greene et 
al. [21] have observed a portion of eystine uptake by 
mouse fibroblast lysosomes which appears to be insen- 
sitive to inhibition by various known competitive in- 
hibitors of lysosomal cystine uptake. Forster et al. [37] 
have offered an alternate explanation for the enhanced 
loss of eystine from cystinotic fibroblasts at elevated 
temperatures. They suggest that the genetic defect in 
cystinosis decreases but does not totally eliminate '?~so- 
somal eystine transport activity, such that residual ~!~'s- 
tine transport activity is increased at elevated teml~,;,a- 
tures due to an increase in membrane fluidity and 
porter mobility. This hypothesis requires the unlikely 
possibility that the genetic defect in the three different 
forms of cystinosis be similar, in order for this hypothe- 
sis to be compatible with the observation of enhanced 
eystine loss from eystinotic fibroblasts at elevated tem- 
peratures by Lemons et al. [36] in five different unre- 
lated eystinotic families representing the three differ- 
ent forms of cystinosis. 
III-B. The cystine dimethyl ester selection technique 
The methyl ester loading technique has been ex- 
ploited to develop a selection method highly cytotoxic 
for eystinotic fibroblasts but not normal fibroblasts [38]. 
Cystine is specifically loaded into lysosomes of normal 
and eystinotic ceils with cystine dimethyl ester (CDME). 
Since lysosomal eystine transport is impaired in 
cystinotic cells, exposure to CDME results in continu- 
ous loading of eystine into cystinotic lysosomes without 
any means of cystine escape, eventually causing cell 
death. In contrast, lysosomes of normal cells are able 
to transport cystine out of their lysosomes, thereby 
protecting lysosomes from rupturing if the rate at which 
cystine forms within lysosomes does not greatly exceed 
the rate of lysosomal cystine exodus. Exposure to 2 
mM CDME for 20 min was found to completely de- 
stroy some cystinotic fibroblast cell lines yet retain 
good cell viability in normal fibroblast cell lines [38]. 
The conditions for CDME cytotoxie selection vary 
somewhat for different cell lines. After transfecting a 
cystinotic cell line with normal human genomic DNA 
in an appropriate vector, exposure to cystine dimethyl 
ester should permit selecting only those cells which 
have incorporated and expressed the lysosomal cystine 
transport gene. Standard techniques of gene rescue 
could then be applied to identify the lysosomal cystine 
transport gene. 
III-C. Cationic amino acid transport: lysosomai system c 
Carrier-mediated transport of cationic amino acids 
across the lysosomal membrane has been demonstrated 
in human fibroblasts by analog inhibition analysis of 
the lysosomal uptake of L-[14C]arginine [39] and char- 
acterization of a trans-stimulation property associated 
with L-[14C]lysine exodus from human fibroblast lyso- 
somes [31]. In the latter study, 2 mM L-lysine, added to 
the buffer in which lysosomes were suspended, trans- 
stimulated L-[14C]lysine exodus from fibroblast lyso- 
somes approx. 2-fold, decreasing the half-time of exo- 
dus from approx. 24 min to approx. 12 min at pH 6.5 
and 25°C (Fig. 3). trans-stimulation of L-[14C]lysine 
exodus from fibroblast lysosomes was selective for the 
L-isomer of lysine and was dependent on the concen- 
tration of external lysine, obtaining maximal trans- 
stimulation using extralysosomal [Lys] > 2 mM (Fig. 4). 
In addition to lysine, the cationic amino acids arginine, 
ornithine, 2-aminoethyl-L-Cysteine and L-2,4-diamino- 
butyrate were all capable of trans-stimulating L- 
[14C]lysine efflux from human fibroblast lysosomes. In 
contrast, neutral and anionic amino acids had no effect 
on L-[14C]lysine efflux from fibroblast lysosomes 
demonstrating the specificity of this trausport system 
for cationic amino acids. The rate of L-[~4C]lysine exo- 
dus and its trans-stimulation by cationic amino acids 
was very similar for lysosomes isolated from either 
normal or cystinotic human fibroblasts indicating that 
cystinotic fibroblasts have normal levels of lysosomal 
system c activity. 
The same general substrate specificity for this car- 
rier of cationic amino acids was observed in a subse- 
quent investigation analyzing the ability of different 
amino acid analogs to inhibit the lysosomal uptake of a 
model cationic amino acid, L-[14C]arginine [39]. Argi- 
nine uptake by human fibroblast lysosomes exhibited 
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Fig. 3. trans-Stimulation of L-[u4C]lysine exodus from human fibro- 
blast lysosomes by extralysosomal L-lysine. Lysosomes from normal 
human fibroblasts were loaded with L-[mC]lysine by incubation with 
i]4C]lysine methyl ester. Lysine-loaded lysosomes were incubated at 
25°C in the presence or absence of 2 mM L-lysine in 50 mM 
Mops-Tris buffer (pH 6.5) containing 0.25 M sucrose and 1 mM 
Na2EDTA. At the indicated time points, lysosomes were collected 
on glass fiber filters, washed and counted for radioactivity [31]. 
complete saturability with a K m of 0.32 mM at pH 7.0 
and 37 °C (Fig. 5) and was competitively inhibited by 
L-homoarginine, L-lysine, L-ornithine and 2-aminoeth- 
yl-L-cysteine with inhibition constants (K~) ranging from 
0.8-1.2 mM. This K m of lysosomal arginine uptake is 
8-times greater than the Km for arginine transport 
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Fig. 4. Dependence of trans-stimulation of L-[ X4C]lysine exodus from 
human fibroblast lysosomes on the concentration of external lysine. 
The nail-time of L-[14C]lysine exodus from human fibrobla~t iyso- 
somes was determined for iysosomes incubated at 25 ° C, in pH 6.5 
buffer containing unlabelled L-lysine at the concentration indi- 
cated [31]. 
across the plasma membrane of human fibroblasts by 
system y+ [40]. Several other differences were revealed 
for cationic amino acid transport by lysosomal system c 
and by system y+ of the plasma membrane: (i) arginine 
transport across the plasma membrane by system y+ is 
relatively insensitive to pH over the range from pH 5-8 
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Fig. 5. Kinetics of the initial rate of arginine uptake into human fibroblast lysosomes as a function of L-arginine concentration• Fibroblast 
lysosomes were incubated for 1.5 rain at 37 o C in pH 7.0 buffer containing L-[t4C]arginine at the indicated concentration. At the completion of 
the incubation period, lysosomes were filtered• washed and counted for radioactivity. A, Michaelis-Menten plot of the initial rate of arginine 
uptake as a function of the arginine concentra,Jon; B, Lineweaver-Burk plot of the same data. A small non-saturable component of K d = 0.1 
pmol of arginin,~ hex-n rain-1 raM-t  has been subtracted from the data [39]. 
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10-times faster at pH 7 than at pH 5 [39], (ii) in the 
presence of Na +, ,:ertain neutral amino acids such as 
homoserine and e-hydroxy-a-aminocaproate are ac- 
cepted as surrogate substrates by system y+ [41,42] but 
not by lysosomal system c [39], (iii) a-N-methyl-t.- 
arginine (K i = 0.5 mM), D-arginine (K i = 1.5 mM), and 
e-tfimethyl-L-lysine (K i = 4.5 mM) are recognized by 
lysosomal system e, whereas these analogs are poorly 
recognized by system y+ [40]. This latter finding indi- 
cates that lysosomal system c has a slightly broader 
substrate specificity than system y+, tolerating methyla- 
tion of the a-amino group or side chain distal amino 
group and only moderately discriminates between L- 
and D-stereoisomers. Methylation of the a-carboxyl 
group is not accepted, however, as demonstrated by 
the failure of lysine methyl ester to inhibit lysosomal 
arginine uptake [39]. L-2,4-Diaminobutyrate is the 
shortest cationic amino acid recognized by lysosomal 
system c, as indicated by its ability to inhibit lysosomal 
arginine uptake and trans-stimulate lysosomal lysine 
exodus. In contrast, L-2,3-diaminopropionate has no 
effect on lysosomal arginine uptake. 
The effects of the lysosomal transmembrane poten- 
tial and proton gradient on lysosomal system c trans- 
port activity have not been studied. However, MgATP 
has been shown to exert opposite effects on efflux and 
influx. Lysine efflux is accelerated 2-fold upon exposing 
lysosomes to 2 mM MgATP at pH 6.5 and 25 °C [31]. 
In contrast, the initial rate of lysosomal arginine up- 
take is retaroed 3-fold when 2 mM MgATP is added to 
incubation mixtures at pH 7 and 37 *C [39]. In addi- 
tion, lysine efflux from fibroblast lysosomes increases 
approx. 1.4-fold as the extralysosomal buffer pH is 
raised from pH 5.5 to 7.6 [31], whereas arginine uptake 
increases 10-fold as the pH of the incubation medium 
is raised from pH 5 to 7 [39]. 
III-D. Cysteamine treatment of cystinosis and lysoaomal 
transport system c 
Addition of cysteamine to cultures of eystinotic fi- 
broblasts produces rapid intralysosomal eystine deple- 
tion [43]. This effect is concentration-dependent and 
has been shown to be the result of mixed disulfide 
formation inside lysosomes between cysteamine and 
cystine [31,39,44]. The two products of this reaction, 
cysteine and the mixed disulfide of cysteamine and 
cysteine, are transported out of eystinotie lysosomes by 
other transport routes which are not defective (Fig. 6) 
[31,39,44]. The mixed disulfide of eysteamine and cys- 
teine is an analog of lysine and is recognized by lysoso- 
real system c with an affinity equal to that of lysine 
[39]. Cysteamine is relatively nontoxic and well toler- 
ated. Treatment of a large population of cystinotic 
patients with cysteamine for periods of several years 
showed improved linear growth and stabilization of 
renal function incidental to this treatment. Cysteamine 
therapy of nephropathic cystinosis has become ac- 
cepted as useful in averting the otherwise catastrophic 
renal failure which occurs in cystinosis [45]. 
Any compound that can e, ter  lysosomes, form a 
mixed disulfide with cystine and whose product can be 
transported by existing carrier systems in the lysosomal 
membrane will be a potential cystine depleter and a 
potentially effective agent in the treatment of nephro- 
pathic cystinosis. Other agents known which perform in 
this way include thiocholine, which reacts to form a 
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Fig. 6. Reaction of cysteamine and cystine [43]. 
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and mercaptoethylgluconamide which may undergo hy- 
drolysis inside the cell to liberate free cysteamine prior 
to mixed disulfide formation [46]. 
III-E. Dicarboxylic amino acid transport: lysosomal sys- 
tem d 
Collarini et al. [47] have characterized a transport 
system, designated as lysosomal system d, that serves 
for the passage of anionic amino acids across the 
membrane of human fibroblast lysosomes. Glutamate 
and aspartate were taken up by fibroblast lysosomes by 
a single, high affinity transport system displaying a K m 
of 4-12 /zM for glutamate and aspartate. Lysosomal 
aspartate uptake linearly increases over the pH range 
from 5.5 to 8.0 displaying 2-3-fold greater uptake at 
pH 8 than at pH 5.5. A small trans-stimulation of 
[3H]glutamate uptake is observed when uptakes are 
performed with lysosomes pre-ioaded with unlabelled 
glutamate. Efflux of glutamate from human fibroblast 
lysosomes occurs rapidly with a t~/2 of 5-7 rain at pH 
7.0 and 37 ° C. This transport system is similar in speci- 
ficity to the plasma membrane anionic amine acid 
transport system, XAG, with the exception that lysoso- 
mal system d is not dependent on Na ÷ ions and has a 
broader substrate specificity in terms of substrate 
length, size and stereospecificity [48-51]. The maxi- 
mum chain length permissible for recognition by lyso- 
somal system d appears to be six carbons as indicated 
by the ability of L-a-aminoadipate t6 inhibit glutamate 
uptake strongly, whereas L-a-aminopimelate is ineffec- 
tive. Only a small discrimination is made between the 
D- and L-stereoisomers of aspartate and glutamate, but 
as the chain length increases to 6 carbons, in the case 
of a-aminoadipate, strong preference is given to the 
L-stereoisomer. N-Methylation of either L-glutamate or 
L-aspartate greatly reduces their recognition by lysoso- 
mal system d. The cyclic glutamate analog, kainate, is 
poorly recognized as is the B-anionic amino acid, 3- 
aminoglutarate. 
III-F. Transport of  the small neutral amino acids: sys- 
tems e, f and p 
The lysosome membrane, similar to the plasma 
membrane, contains multiple pathways for the trans- 
port of small neutral amino acids. Studies of lysosomal 
proline, alanine, serine and threonine uptakes have 
revealed the existence of at least three separate Na+- 
independent routes mediating the passage of small 
neutral amino acids across the human fibroblast iysoso- 
mal membrane [14]. ARhough the broad outlines dis- 
tinguishing these transport systems from one another 
have been established, considerably more investigation 
is required to understand the many specific character- 
istics of each route. The majority of information has 
come from the investigation of lysosomal proline up- 
take. Lysosomal proline uptake displays a broad maxi- 
mum in the neutral pH range centered near pH 6.4 
and declines at pH values below 6.0 or above 7.0. 
Proline uptake is highly selective for the L-stereoisomer 
of pro!ine and is strongly inhibited by small neutral 
amino acids with sidechains 1-2 carbons in length 
including the B-amino acids, 3-aminoisobutyrate and 
B-alanine. In contrast, anionic and cationic amino acids, 
or neutral amino acids having side chains > three 
carbons in length are poor inhibitors of lysosomal 
proline uptake. The analogs, 2-(methylamino)-iso- 
butyrate [MeAIB] and 2-aminoisobutyrate [2-AIB], 
which strongly inhibit proline transport across the 
plasma membrane of the human fibroblast, only weakly 
inhibit proiine uptake by fibroblast lysosomes. The 
weak inhibition by MeAIB and 2-AIB suggests that 
excessive branching off of the a-carbon is not permissi- 
ble for recognition by the transport protein. Finally, 
small neutral amino acid analogs in which the a-amino 
group is mono-N-methylated [e.g. sarcosine, a-N- 
methyl-L-alanine] are good inhibitors of lysosomal pro- 
line uptake but analogs in which the a-amino group is 
further methylated [N,N-dimethylglycine, betaine] are 
incapable of inhibiting proline uptake. 
Proline uptake by human fibroblast lysosomes shows 
complete saturation at [Pro] _> 0.4 raM. Lineweaver- 
Burk and V/S  vs. V plots are non-linear, however, 
indicating that at least two different pathways are 
involved in lysosomal proline uptake. K m values of 
0.01 mM and 0.07 mM were found for the two differ- 
ent routes of carrier mediation with the higher affinity 
route accounting for 60-70% of the total proline up- 
take. Additional support for the existence of at least 
two transport routes mediating lysosomal proline up- 
take came from studies showing that approx. 75% of 
total proline uptake is sensitive to inhibition by ala- 
nine, whereas the remaining 25% of pro!ine uptake is 
not inhibited by alanine (Fig. 7). The route selving for 
the majority of lysosomal proline uptake, which also 
recognizes alanine, was designated lysosomal system f. 
Nearly complete inhibition of L-[~4C]proline uptake 
was obtained with L-proline and 3,4-dehydro-L-proline, 
suggesting that these two amino acids are recognized 
not only by the alanine-sensitive route (system f) but 
also by the second route of lower affinity which is not 
inhibited by alanine. This latter route was designated 
system p, for proline specific route (Fig. 8). 
Studies of [14C]alanine, [14C]serine and [14C]threo- 
nine uptake by human fibroblast lysosomes revealed 
that, in addition to systems f and p, at least one other 
transport system serves for carrier mediation of small 
neutral amino acids across the fibroblast lysosomal 
membrane [14]. This transport system, designated sys- 
tem e, mediates the majority of alanine, serine and 
threonine uptake by human fibroblast lysosomes but 
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Fig. 7. Concentration dependence of inhibition of praline uptake into human fibroblast lysosomes by various amino acids. The uptake of 0.03 mM 
L-[14C]proline into lysosomes was measured for 2.5 rain at pH 7.0 and 37 °C in the presence of various amino acids at concentrations ranging 
from 0 to 3.0 raM. The uninhibited control uptake was 0.23 pmol praline/unit of latent hexosaminidase activity [14]. 
does not recognize praline or other small neutral amino 
acids in which the a-amino group is a secondary amine 
(e.g. sarcosine, a-N-methyl-L-alanine). Whereas ala- 
nine inhibits L-[14C]proline uptake by 70-80%, high 
concentrations of praline inhibit alanine, serine or 
threonine uptakes by only 10-20%. In addition, leucine, 
which has no effect on lysosomal praline uptake, in- 
hibits lysosomal alanine and threonine uptakes by 60- 
70%. In one respect, the lysosomal transport systems 
shown in Fig. 8 bear a strong analogy to the Na+-de - 
pendent transport systems, ASC and A, present on the 
plasma membrane of human fibroblasts. System ASC, 
similar to lysosomal system e, provides for the majority 
of alanine and serine transport across the fibroblast 
plasma membrane [50-52] but excludes amino acids in 
which the a-amino group is methylated. The minor 
route of transport, system A, similar to lysosomal sys- 
IAle. Ser, Thr I 
A i 
/ I I Jpr, I 
~dehydro-Pro]  
Fig. 8. Schematic diagram of the proposed transport systems for 
small neutral amino acids in the lysosome of the human fibre- 
blast t 14]. 
tern f, recognizes small neutral amino acids including 
those in which the a-amino group is a secondary amine. 
III-G. Transport of the large neutral, hydrophobic amino 
acids: lysosomal system h 
A carrier-mediated transport system recognizing the 
large neutral amino acids was first demonstrated by 
Bernar et al. [20]. They observed transstimulation of 
[3H]tyrosine uptake by lysosomes of FRTL-5 cells after 
lysosomes were pre-loaded with tyrosine using the 
methyl ester loading technique. The specificity of this 
trans effect was shown by the inability of pre-loaded 
cystine to transstimulate [3H]tyrosine uptake. The ini- 
tial rate of [3H]tyrosine uptake by FRTL-5 lysosomes 
increased proportionately to the amount of unlabelled 
tyrosine loaded into the lysosomes until apparent satu- 
ration was achieved with intralysosomai tyrosine con- 
centrations of 1-2 nmol of tyrosine loaded/unit of 
hexosaminidase activity. Analog inhibition analysis of 
[3H]tyrosine uptake revealed that this transport system 
specifically recognizes the large neutral amino acids. 
Isoleucine, leucine, tryptophan, tyrosine, phenylalanine 
and histidine strongly inhibited [3H]tyrosine uptake by 
FRTL-5 lysosomes. Valine and methionine moderately 
inhibited tyrosine uptake, whereas cystine, and anionic, 
cationic and small neutral amino acids did not inhibit 
lysosomal tyrosine uptake. The L-stereoisomer of the 
large neutral amino acids was strongly preferred com- 
pared to the D-stereoisomer [20] and tyrosine uptake 
obeyed Michaelis-Menten kinetics displaying a K m of 
20/zM at pH 7.0 and 37 °C [53]. Exposure of FRTL-5 
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lysosomes to 2 mM MgATP or 5 mM N-ethylmalei- 
mide had little effect on tyrosine uptake [20]. 
Exodus of tyrosine from lysosomes of FRTL-5 cells 
occurs ve~ quickly at 37 ° C, with a tl/2 of approx. 2 
rain. In contrast, tyrosine exodus from human leuco- 
cytes is very slow at 37 °C showing only about a 10% 
loss after a 30 min incubation [20]. Other large neutral 
amino acids, however, were found to egress from leu- 
cocyte lysosomes at a moderate rate displaying half- 
times of 17-26 rain at 37 °C for methionine, cysteine 
and tryptophan [54]. 
Lysosomal transport of large neutral amino acids 
has also been observed in huma,  .fibroblasts which 
exhibit some notable differences from !ysosomal system 
h of FRTL-5 ceils. Stewart et al. [55] found a low level 
of lysosomal uptake of large neutral amino acids by 
human fibroblast lysosomes [55]. Non-saturable uptake 
predominated when lysosomal uptakes were performed 
with millimolar concentrations of phenylalanine, 
leucine, or tryptophan. At much lower concentrations 
of these substrates, however, uptake was saturable, 
displaying K m values of 5-30 tzM which ,".re similar to 
the K m values found for lysosomal system h transport 
activity in FRTL-5 cells. Patterns of analog inhibition 
analysis, however, suggest that passage of large neutral 
amino acids across the fibroblast lysosomal membrane 
may be mediated by more than one route. The L-stere- 
oisomer of inhibitory analogs was only slightly more 
effective than o-stereoisomers in striking contrast to 
lysosomal system h of FRTL-5 cells which is highly 
selective for the L-stereoisomer. 
The Fischer rat thyroid cell line, FRTL-5, in which 
lysosomal system h has been characterized, retains 
many of the functional characteristics of thyroid tissue 
such as thyroglobulin synthesis, iodide uptake, cyclic 
nucleotide metabolism and response to thyrotropin. 
Harper et al. [56] found that lysosomal tyrosine coun- 
tertransport increased an average of 7-fold when 0.1 
nM TSH was added to the culture medium in which 
FRTL-5 cells were grown. An exposure time of 2-4 
days was required in order to observe this level of 
stimulation in lysosomal tyrosine countertransport by 
TSH. In addition, lysosomal countertransport of two 
other lysosomal system h substrates, phenylalanine and 
leucine, was increased in FRTL-5 cells incubated with 
TSH. In contrast, lysosomal cystine countertransport 
which has been observed in FRTL-5 cells is not af- 
fected by culturing in media containing TSH. The 
enhancement of tyrosine countertransport activity by 
TSH could be mimicked by cAMP and cholera toxin 
suggesting that the TSH stimulatory activity was medi- 
ated by a cAMP signal. TSH stimulation of lysosomal 
tyrosine countertransport activity was completely inhib- 
ited by 100 tzM cycloheximide or 25 nM actinomycin D 
indicating that de novo protein synthesis was required 
in order to observe TSH stimulation of tyrosine coun- 
tertransport. Neither cycloheximide or actinomycin D 
affected the ability of TSH to increase cAMP levels in 
FRTL-5 cells. These results provide the first demon- 
stration of a lysosomal transport system under hor- 
monal regulation. Since lysosomes are a major site for 
thyroglobulin degradation, up-regulation of lysosomal 
system h by TSH in thyroid cells may be important to 
salvage tyrosine efficiently for maintaining a high over- 
all rate of thyroglobulin synthesis thereby supporting 
thyroxine formation and release. As suggested by 
Harper et al., hormonal regulation of other lysosomal 
transport systems may exist when the carriers fulfill 
salvage roles or are inherently involved in production 
of regulatory signals relevant to the differentiated 
functions of a particular cell type. 
The role of lysosomai system h in salvaging metabo- 
lites from th~roglobulin degradation in FRTL-5 cells 
was further shown by Tietze et al. [57] and Andersson 
et al. [53] who demonstrated that the metabolite, 
monoiodotyrosine, is also transported by lysosomal sys- 
tem h. Lysosomes pre-loaded with monoiodotyrosine 
transstimulated the lysosomal uptake of tyrosine, 
leucine, phenylalanine and moniodotyrosine but not 
cystine. Monoiodot3'rosine uptake by FRTL-5 lyso- 
somes was competitivel¢ inhibited by other system h 
substrates, displayed maximal uptake near pH 7.5 and 
was stimulated 4-9-fold by culturing FRTL-5 cells in 
media containing TSH. Lysosomal system h recognizes 
monoiodotyrosine with greater affinity than tyrosine, 
displaying a K m of 1.5-1.8 ~,M for monoiodotyrosine 
compared to the K m of 20/~M for tyrosine uptake [53]. 
Similar to monoio'dotyrosine, phenylalanine derivatives 
containing a halogen substituent on the phenyl ring 
were stronger competitive inhibitors than phenyl- 
alanine. In addition, leucine inhibited lysosomal 
monoiodotyrosine and tyrosine uptake with a K i of 3.2 
p.M and 3.5/~M, respectively. Tyramine and 3-(p-hy- 
droxyphenyl)-propionic acid do not inhiifit lysosomal 
monoiodotyrosine uptake, indicating that both the a- 
carboxyl and a-amino groups of tyrosine are important 
for recognition by the system h transport protein. 
III-H. The cysteine-specific lysosomal transport system 
Whereas many of the transport systems associated 
with lysosomes are thought to function mainly for the 
export of metabolites out of lysosomes, a cysteine- 
specific lysosomal transport system has been described 
which appears to serve as a major route for the deliv- 
ery of thiol into human fibroblast lysosomes [58]. The 
initial evidence for the existence of this transport sys- 
tem came from an investigation of the uptake of L- 
[3SS]cystine by intact human fibroblasts. When huma~ 
fibroblasts were incubated for 2-5 min with 20 /zM 
L-[3SS]eystine, 50-60% of the total radioactivity taken 
up by the cells was found to be associated with the 
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lysosomal compartment in the form of cysteine. This 
amount of cysteine sequestration in such a short time 
interval is amazing when one considers that lysosomes 
constitute only 4% of the intracellular volume of a 
normal human fibroblast [59]. Using Percoll-purified 
lysosomes it was found that a single transport route, 
highly specific for cysteine, served for the uptake of 
cysteine into human fibroblast lysosomes. The 
cysteine-specific transport system is present in both 
normal and cystinotic human fibroblasts, displays a K m 
of 53 pM for cysteine uptake at pH 7.0 and 37°C and 
exhibits the highest activation energy of any known 
lysosomal transport system (Ea = 21 kCal/mol, Qm0 ffi 
3.2). The highly selective substrate specificity of this 
transport system is reflected by the lack of inhibitory 
effect of 5 mM concentrations of other neutral, cationic, 
or anionic amino acids on the lysosomal uptake of 35 
/zM L-[35S]oTsteine. Analogs very similar in size and 
structure to cysteine, such as serine, penici~lamine, 
homocysteine and alanine are at best only weakly in- 
hibitory. In addition, D-cysteine and the deaminated 
analog of cysteine, /3-mercaptopropionate, have little 
effect on lysosomal cysteine uptake, whereas the decar- 
boxylated analog of cysteine, cysteamine, is a good 
inhibitor of lysosomal cysteine uptake. These results 
indicate that the cysteine-specific transport route is 
highly selective for the L-stereoisomer and has a strin- 
gent requirement for a sidechain thiol and an a-amino 
group while not accomodating amino acids having 
sidechains longer than that found in cysteine. The 
a-carboxy group of cysteine, however, does not appear 
to be required for recognition in that cysteamine 
strongly inhibits lysosomal cysteine uptake. 
The pH curve of the cysteine-specific lysosomal 
transport system is well suited for the delivery of 
cysteine into lysosomes. Very little uptake of cysteine 
by fibroblast lysosomes is observed over the acidic pH 
range from pH 4.8-6.0, but then the transport rate 
increases 7-10.fold between pH 6 and 7.5 (Fig. 9). If 
this pH dependence exists on both sides of the lysoso- 
real membrane, then cysteine influx into fibroblast 
lysosomes originating at the cytosolic pH of 7.0 would 
be greatly favored over cysteine efflux from lysosomes 
originating at the intralysosomal pH of 5.3, thereby 
favoring net cysteine accumulation within lysosomes. 
The large amounts of cysteine delivered into lyso- 
somes by the cysteine-specific transport route may sup- 
port lysosomal proteolysis in two different ways: by 
providing thiol necessary to maintain maximal activity 
of the iysosomal thiol-dependent proteinases and sec- 
ondly by reducing protein disulfide bridges during pro- 
teolysis. Several studies have shown that thiols such as 
cysteine and GSH increase the rate at which disulfide- 
rich proteins are degraded by lysosomal proteinases, 
including degradation by prote;nases which are not 
thiobdependent [60-62]. Kooistra et al. [60] postulated 
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Fig. (~. pH profile of 0.034 mM ,~-[3sS]cysteine uptake by human 
fibroblast iysosomes [58]. 
that thiols reduce protein disulfide bridges during pro- 
teolysis within lysosomes, allowing proteins to unfold, 
thereby providing proteinases greater access to newly 
exposed, susceptible peptide linkages within the sub- 
strate [60]. A recent invest;gation by Feener et al. [63] 
has challenged whether protein disulfides can be re- 
duced within lysosomes. In this latter study, Chinese 
hamster ovary (CHO) cells were allowed to endocytose 
the synthetic disulfide, [~251]tyn-SS-PDL, which was 
prepared by conjugating poly-D-lysine (molecular mass 
approx. 60 kDa) to tyramine via a 3-(propionyldithio) 
propionic acid linkage and then iodinating the conju- 
gated tyramine residues. Following endocytic uptake, 
[~I]tyn-SS-PDL was found to be delivered to lyso- 
somes but only 5% of its disulfide bonds were reduced 
within the lysosomes of intact cells during a 4 h incuba- 
tion at 37 ° C. When 0.2 mM cystamine was added to 
the culture medium during the 4 h incubation, 29% of 
the disulfide bonds in [125I]tyn-SS-PDL were reduced 
within the lysosomes of CHO cells. Feener et al. con- 
cluded that under normal culture conditions, reduction 
of [125I]tyn-SS-PDL is not detectable within lysosomes, 
ruling out lysosomes as a meaningful site of reductive 
cleavage, hut exposing lysosomes to cysteamine can 
transform lysosomes into a reducing compartment. 
Thoene et al. [43] have shown previously that 0.1 mM 
cysteamine can rapidly reduce large quantities of cys- 
tine within lysosomes of cystinotic fibroblasts, causing 
50% reduction of the disulfide bonds within 15 min. In 
comparison, cleavage of only 29% of the disulfide 
bonds in [tzsI]tyn-SS-PDL when cells are exposed to 
0.2 mM cystamine for 4 h is an extremely slow rate of 
disulfide bond reduction which raises questions regard- 
ing the validity of using [t251]tyn-SS-PDL for measuring 
lysosomal disulfide bone reduction. If such a slow rate 
of reducing the disulfide bonds in tyn-SS-PDL is ob- 
served when cells are ¢dtured in media containing 
cystamine, it is not unexpected that even fewer of the 
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disulfide bonds in tyn-SS-PDL are reduced when cells 
are cultured in media lacking cystamine. Furthermore, 
in view of the recent finding of long chains of inorganic 
polyphosphate within human fibroblast lysosomes (see 
section VI-C), the tyramine-poly-D-lysinc conjugate, 
being highly cationic, likely will become tightly associ- 
ated with lysosomal inorganic polyphosphate which 
may restrict access of thiols to susceptible disulfide 
linkages. In conclusion, the slow rate of disulfide re- 
duction of [125I]tyn-SS-PDL in lysosomes may be more 
a reflection of limited access to the disulfides of this 
~d~ghly cationic synthetic substrate than an indication of 
~e, overall ability of thiols to reduce protein disulfide 
bridges within lysosomes. 
Two different cycles involving the interchange be- 
~veen cystine and cysteine are now apparent which 
~erve the requirements for cellular metabolism within 
the cytosolic and lysosomal compartments of the hu- 
man fibroblast (Fig. 10). Cystine is transported across 
the plasma membrane into the cytosol by the XcG 
transport system [64]. Upon entering the cytosol, cys- 
tine is reduced by GSH to form cysteine and the mixed 
disulfide of glutath:,one and cysteine, with much of this 
latter product being further metabolized. Cysteine 
formed in the cytosol can be transported back into the 
extracellular space by several transport routes, where it 
is reoxidized to form cystine [50,65-68]. Cytosolic cys- 
teine can also be used for the synthesis of glutathione 
and proteins, metabolized for the production of other 
cellular constituents, or sequestered into lysosomes by 
the cysteine-specific lysosomal transport system to aid 
lysosomal proteolysis. Once within the lysosomal com- 
partment, cysteine can react with protein disulfide 
bridges, as suggested by Lloyd [69], forming equimolar 
amounts of protein-linked cysteine and cystine at the 
site of each original disulfide bridge, which after prote- 
olysis are released into the lysosome as free cystine and 
cysteine. Cystine is transported out of the lysosome 
into the cytosol by the lysosomal cystine transport 
system. Upon reaching the cytosol, cystine is reduced 
back to cysteine by GSH. The manner by which cys- 
teine is transported from lysosomes remains to be 
determined. Lysosomal ~'steine exodus could be facili- 
tated in o~rt by the cysteine-specific lysosomal trans- 
cystino ~ ~ 02 cysteine 
Fig. 10. Schematic diagram showing (a) the interconversion between cystine and cystein¢ in different cellular compartm¢nts, (b) the role of 
transport systems in maintaining this cycle and (c) the role of cysteine in supporting lysosomal proteolysis. The shaded area represents the 
cytosol, whereas the clear area represents the lysosomal compartment; ASC, L,asc and XcG are plasma membrane amino acid transport systems 
[58]. 
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port route and also by lysosomal systems e and f, which 
both recognize a broad range of small neutral amino 
acids. For the present time, we have shown these latter 
two transport routes as being likely candidates in play- 
ing a major role in mediating lysosomal cysteine egress. 
Cysteamine and thiocholine are each capable of 
rapidly depleting cystinotic fibroblasts of intralyso- 
somal cystine accumulations, yet the mechanisms which 
serve for the delivery of these two agents into lyso- 
somes are not known. The ability of cysteamine to 
strongly inhibit cysteine uptake by the cysteine-specific 
lysosomal transport s~,,~em indicates that cysteamine is 
recognized by this travsporter. Analog inhibition stud- 
ies of radiolabelled cysteamine uptake by lysosomes 
are necessary, however, to prove that this transport 
route actually serves for the delivery of cysteamine into 
lysosomes. 
IV. Sugar transport systems 
IV-A. Salla disease and the lysosomal transport of acidic 
monosaccharides 
Similar to the discovery of the lysosomal cystine 
transport system, the detection of a lysosomal transport 
z~oute mediating the passage of sialic acid and other 
acidic monosaccharides across the lysosomal mem- 
brane resulted from efforts by several investigators to 
understand the basis of two rare genetic disorders, 
Salla disease and infantile sialic acid storage disease 
(ISSD). In these two disorders, excessively high con- 
centrations of free sialic acid are found in various 
tissues [24]. Biochemical studies did not reveal any 
defect in the major cellular enzymes involved in 
metabolism of sialic acid, and the concentration of 
glycoproteins, glycolipids and gangliosides within af- 
fected tissues ~vere in the nonnal range. The clue to 
the role of lysosomes in this disorder came from elec- 
tron microscopic and histochemical studies which indi- 
cated that the large accumulations of free sialic acid in 
Salla disease were contained within the lysosomal com- 
partment [70-72]. Renlund et al. [73,74] then demon- 
strated that lysosomal degradation of sialic acid-con- 
taining glycoconjugates was normal but egress of free 
sialic acid from lysosomes was retarded greatly in SaUa 
disease fibroblasts. In this latter study, lysosomes of 
normal and Salla disease fibroblasts were loaded with 
sialic acid to comparable levels by incubating cells with 
high concentrations of the sialic acid precursor, N- 
acetylmannosamine. Subsequent measurement of sialic 
acid loss from lysosomes demonstrated almost no exo- 
dus of sialic acid from Salla disease fibroblasts, whereas 
substantial efflux of sialic acid was observed from lyso- 
somes of normal fibroblasts, with the rate of exodus 
being linearly proportional to the amount of sialic acid 
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Fig. 11. Sialic acid uptake by rat liver lysosomal vesicles in the 
presence or absence of a proton gradient. Rat liver lysosomal mem- 
brane vesicles, prepared in 20 mM NaHepes buffer (pH 7.4), were 
pre-incubated for 10 rain at 20 °C in 20 mM NaHepes buffer (pH 
7.4) (o e; A A), or 20 mM NaHepes/40 mM MES 
buffer (pH 5.5) containing 0.01 mM monensin (o o). Subse- 
quently, transport of 0.1 mM [~4C]NeuAc was me-".sured at 20 °C in 
20 mM NaHepes buffer (pH 7.4) (zx - -  A; pH in ffi PHout ffi 7.4), 
or in 20 mM NaHepes/40 mM MES buffer (pH 5.5) containing 0.01 
mM monensin (o o;  PHin ffi pHou t ffi 5.5), or in 20 mM Na- 
Hepes/40 mM MES (pH 5.5) (e o; pHin= 7.4> pHou t = 
5.5) [16]. 
sialic acid transport in lysosomes of Salla disease fi- 
broblasts was confirmed subsequently by several other 
investigators [?5-77]. 
Further investigation by Mancini et al. [16] using rat 
liver lysosomal membrane vesicles provided an under- 
standing c: ,he kinetic properties and overall substrate 
specificity of this carrier serving for lysosomai transport 
of sialic acid. The initial rate of sialic acid uptake by 
rat liver lysosomal vesicles is increased 10-25-fold by 
the presence of an inwardly directed proton gradient 
(PHou t = 5.5 > PHin = 7.4) (Fig. 11). Under these con- 
ditions, sialic acid uptake by rat liver lysosomal vesicles 
is saturable with a K m of 0.24 mM at 20 ° C. The K m 
of sialic acid uptake at pH 5.5 in the absence of a 
proton gradient, however, is 3-fold greater than the K m 
at pH 5.5 in the presence of a proton gradient. A Hill 
plot of the effect of [H +] on proton gradient-depen- 
dent sialic acid uptake did not detect any significant 
degree of cooperativity of protons in accelerating the 
rate of lysosomal sialic acid uptake. In the absence of a 
proton gradient, the carrier fails to exhibit an acidic or 
alkaline pH optimum giving similar rates of siali, acid 
uptake at pH 5.5 (in = out) and at pH 7.4 (in ffi out). 
Furthermore, sialic acid uptake is unaffected by expos- 
ing vesicles to valinomycin undel conditions expected 
to change the membrane potential across the lysosomal 
vesicular membrane. 
Analog inhibition and transstimulation experiments 
revealed that the carrier which recognizes sialic acid is 
actually a group-specific transporter for acidic 
monosaecharides [16]. The uronic and aldonic sugars, 
glucuronate, galaeturonate, gluconate and galactonate 
were strong competitive inhibitors of ['4C]sialic acid 
uptake. In contrast, neutral sugars, anionic amino acids 
and the lactones-gulonolaetone and mannuronolac- 
tone- had little effect on sialic acid uptake. Analogs 
modified at the carboxyl group of carbon 1 or at carbon 
2 were only moderately inhibitory suggesting that both 
of these sites are important in recognition in addition 
to the strict requirement for a negatively charged ter- 
minus. Competitive inhibition constants of 0.11, 0.22, 
0.26 and 1.6 mM were found for glucuronate, N-glyco- 
lylneuraminic acid, gluconate and 2-deoxy-2,3-dehydro- 
N-acetylneuraminic acid, respectively. When lysosomal 
vesicles were pre-loaded with unlabelled sialic acid, 
[14C]sialic acid uptake was transstimulated approx. 10- 
fold. A similar transstimulation of [~4C]sialic acid up- 
take occurred when vesicles were pre-loaded with glu- 
curonate proving actual transport of glucuronate by 
this carrier. 
Similar to the findings with rat liver lysosomal vesi- 
cles, the sialic acid carrier of human fibroblast lyso- 
somes also was shown to transport glucuronic acid, 
displaying a half-time of 2-3 rain for exodus of glu- 
curonic acid at 37 °C [78] and a K m of 0.28 mM [79]. 
Furthermore, not only is free sialic acid stored within 
lysosomes of Salla disease fibroblasts but also glu- 
curon,.'c acid at about 5% of the amount of sialic acid. 
Tietze et al. [80] have demonstrated that the defect in 
infantile sialic acid storage diease (ISSD), like that in 
Salla disease, is due to an impairment in the transport 
system mediating lysosomal passage of sialic acid and 
glucuronate. Salla disease fibroblasts were shown to 
contain approx. 10-times the normal level of free sialic 
acid, whereas ISSD fibroblasts have approx. 100-times 
the normal level of sialic acid. The cause for the 
significantly more severe clinical manifestations and 
greater lysosomal storage of sialic acid in ISSD versus 
Salla disease patients is not yet known. However, one 
speculation is that lysosomes from Salla disease pa- 
tients may have a small amount of residual sialic acid 
carrying capacity that is not apparent by current meth- 
ods of analysis [80]. 
IV-B. The GalNAc / GlcNAc t~ansport system 
Lysosomal degradation of glycosaminoglycans and 
glycoproteins has been shown to produce large quanti- 
ties of N-acetylglucosamine (GIcNAc) and N-acetyl- 
galactosamine (GalNAc) within the lysosomal compart- 
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ment followed by rapid lysosomal efflux of these 
metabolites and their efficient re-incorporation into 
new complex carbohydrates [81]. Recently, Jonas et al. 
[82] described a transport system that displays high 
specificity for GIcNAc and GalNAc in rat liver lyso- 
somes. Lysosomal uptake of these acetylated, amino 
sugars exhibits saturation kinetics with a K m of 4.4 
mM at pH 7.0 and 25 ° C. Uptake of 1 mM [aH]GIcNAc 
or [3H]GalNAc is transstimulated 3-4-fold when up- 
takes are performed with rat liver lysosomes pre-loaded 
with approx. 10 nmol unlabelled GlcNAc/unit /3- 
hexosaminidase activity. The high specificity of this 
transport system is indicated by GalNAc and GIcNAc 
strongly inhibiting the uptake of one another, whereas 
ManNAc (25 mM) inhibited I mM [aH]GIcNAc uptake 
by only 30%. Furthermore, 25 mM glucosamine, glu- 
cose, glucuronic acid, N-acetyln;:araminic acid, man- 
nose, fucose, or various amino acids have little effect 
on the lysosomal uptake of I mM [3H]GIcNAc. Lysoso- 
mal GIcNAc uptake is insensitive to pH in the range 
from pH 6-8 and is not affected by the addition of 5 
mM MgATP or dithiothreitol to incubation mixtures. 
Similar to the lysosomal glucose transporter, cyto- 
cha!asin B strongly inhibits this lysosomal GalNAc/ 
GIcNAc carrier with a 50 #M concentration producing 
90% inhibition of GIcNAc uptake. 
Recently, Jonas and Jobe showed that many of the 
properties of the rat liver lysosomal GIcNAc/GalNAc 
transporter can also be observed using lysosomal mem- 
brane vesicles [19]. Lysosoma! membrane vesicles were 
prepared from Percoll-purified :at liver lysosomes by 
osmotic lysis, facilitated by exposure to 5 mM methion- 
ine methyl ester at pH 7 and 37 °C in the presence of 
protease inhibitors to preserve transport activity [19,83]. 
Membrane vesicles formed in this manne" have a ran- 
dom membrane orientation and are able to acidify the 
intravesicular space in the presence of MgATP indicat- 
ing preservation of lysosomal proton pump activity. 
Lysosomal membrane vesicles pre-loaded with 50 mM 
GIcNAc displayed saturable uptake of [3H]GIcNAc, 
whereas very little uptake of [aH]GIcNAc is observed 
with vesicles not pre-loaded with unlabelled GIcNAc. 
A K m of 1.3 mM was found for GlcNAc countertrans- 
port at 25 °C and pH 7.0 by these lysosomal vesicles; 
this is slightly lower than the K m of 4.4 mM found for 
GIcNAc uptake by intact rat liver lysosomes. GIcNAc 
countertransport by rat liver lysosomal membrane vesi- 
cles also displays a pattern of analog inhibition which is 
similar to that seen with intact rat liver lysosomes. 
Using this system additional characteristics of the 
GalNAc/GIeNAc carrier were revealed: (i) recognition 
by the transport protein does not tolerate phosphoryla- 
tion. or sulfation of GIcNAc at the 1 or 6 position (ii) 
2-N-acetylallosamine which differs from GIcNAc in the 
orientation of the hydroxyl groups at positions 1 and 3 
is recognized nearly as well as GlcNAc and GalNAc; 
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however, moving the acetyl group from position 2 to 
position 6 on GIcNAc or to position 3 of AIINAc 
results in poor recognition by the transporter. Thus, 
orientation of the acetyl group and net charge of the 
sagar are critical structural elements for carrier recog- 
nition, whereas various orientations of the hydroxyl 
groups are permissible. 
Finally, a phenylisothiocyanate derivative of Glc- 
NAc (PITC-GIcNAc) was shown to inhibit GlcNAc 
countertransport by 70% at pH 7.0. This inhibition by 
PITC-GIcNAc is believed to be due to competition at 
the binding site and not due to inactivation since 
covalent modification by this agent is not favorable at 
pH 7. PITC-GlcNAc may serve as a useful probe in 
future studies to specifically label the receptor site of 
the lysosomal GlcNAc/GaINAc transport protein. 
IV-C. Lysosomal transport of glucose and other neutral 
hexoses 
Docherty et al. [84] provided the first experimental 
evidence supporting the existence of a lysosomal trans- 
port system for neutral sugars. They demonstrated tha', 
loss of latency by rat liver lysosomes in osmotic protec- 
tion experiments varied with different neutral hext~ses 
and pentoses, occurred more rapidly with D-stereoiso- 
mers than L-stereoisomers and could be retarded by 
exposure to 1 mM phlorrhizin or 50/~M cytochalasin B 
which have been shown to inhibit other sugar transport 
systems. Subsequently, Maguire et al. [85] demon- 
strated [14C]glucose uptake by rat liver tritosomes ob- 
taining an apparent K m of 48 4- 18 mM at pH 7.4 and 
25 ° C, although the highest concentration used in this 
determination was 20 mM, well below that necessary to 
demonstrate complete saturability of the transport 
route, D-[t4C]Glucose (10 mM) uptake was inhibited 
40-60% by 50 mM concentrations of v-mannose, D- 
glucose or D-2-deoxyglucose and cytochalasin B inhib- 
ited glucose uptake in a dose-dependent manner with 
200 /~M cytochalasin B causing 75% inhibition. The 
strong inhibitory effect of cyW~:halasin B upon lysoso- 
mal glucose transport has also been confirmed by 
Mancini et al. and Jonas et al. [17,86]. 
Recently, Mancini et al. and Jonas et al. have pro- 
vided a further detailed characterization of this lysoso- 
real neutral sugar transport system. Mancini et al. [17] 
demonstrated saturable glucose uptake by membrane 
vesicles prepared from purified rat liver lysosomes. 
Glucose uptake was approx. 2-fold greater when the 
extravesicular pH was in the acidic range from pH 5-6 
than in the neutral pH range from pH 7-8. Imposing 
proton gradients across the vesicular membrane had no 
effect on vesicular glucose uptake indicating that, in 
sharp contrast to lysosomal sialic acid transport, glu- 
cose transport is not coupled to proton gradients. At 
pH 7.4 and 20 ° C, a K m of 75 mM was obtained for 
glucose uptake by lysosomal vesicles, whereas at pH 5.5 
a K m of 90 mM was found with a Vma x 2-fold greater 
at pH 5.5 than at pH 7.4. Similarly, uptake of the 
sugars, D-galactose, D-mannose and L-fucose displayed 
K m values ranging from 50-75 mM at pH 5.5. For all 
these analogs, Lineweaver-Burk and V / S  vs. V plots 
were linear suggesting that only one transport route is 
involved in their uptake by rat liver lysosomal vesicles. 
Most importantly, a transstimulation property, ob- 
served as a 3-fold greater D-[14C]glucose uptake when 
vesicles were pre-loaded with 100 mM D-glucose, was 
used to determine the nature of the substrates trans- 
ported by this carrier and what structural features are 
important for recognition. In addition to glucose, 100 
mM concentrations of the neutral hexoses, v-galactose, 
v-mann~se,  D-fucose, L-fucose and D-fructose 
transstimulated D-[14C]glucose uptake 1.7-3-fold. A 
small transstimulation of D-[14C]glUCOSe uptake was 
also observed with the pentose, D-ribose. In contrast, 
h-stereoisomers of glucose, galactose and rhamnose or 
the acidic sugars, D-gluconic acid, D-glucuronic acid 
and sialic acid had no transstimulatory effect on glu- 
cose uptake. Furthermore, N-acetyl-D-glucosamine, 6- 
amino-D-deoxyglucose, the pentose, v-arabinose and 
the lactones, D-galactonolactone, D-mannuronolactone 
and h-ascorbic acid were also ineffective in transstimu- 
lating glucose uptake by rat liver lysosomal vesicles. In 
conclusion, the lyso~omai glucose transport system rec- 
ognizes neutral hexoses with preference for the D-ster- 
eoisomer except in the case, thus far, for fucose in 
which bGth isomers are recognized. Sugars which are 
N-acetylated, or which contain a lactone, or a charged 
substituent are poorly recognized. The poor ability of 
pentoses to transstimulate glucose uptake suggests that 
pentoses generally are not transported by this carrier. 
Bird et al. [87] and Magnire et ai. [85] have shown that 
D-rihose, at concentrations of 125-250 mM, enters rat 
liver lysosomes at a higher rate than glucose. Since 
D-ribose is poorly recognized by the glucose trans- 
porter, the majority of D-ribose passage across the 
lysosomal membrane most likely occurs by a different 
pathway. Whether this pathway is simple diffusion as 
suggested by Bird et al. [87] or by a carrier-mediat~:d 
route remains to be determined. 
Recently, Jonas et al. [86] using intact rat liver 
lysosomes applied analog inhibition analysis to deter- 
mine the characteristics of the lysosomal glucose trans- 
porter in intact rat liver lysosomes. The same general 
substrate specificity was found as that described above 
for lysosomal membrane vesicles, trans-Stimulation, 
however, was not observed when D-glucose or L-fucose 
uptakes were performed with intact lysosomes pre- 
loaded by equilibration with 100 mM D-glucose. Lyso- 
somal glucose uptake was insensitive to pH over the 
range from pH 6-8 and was not affected by the pres- 
ence of 2 mM MgATP, 5 mM dithiotbreitol, 25 mM 
NaC1, or 25 mM KCI in incubation mixtures. 
The ability of this transport system to remove neu- 
tral sugars quickly from the iysosomal compartment is 
suggested by the rapid efflux of D-glucose from rat liver 
lysosomes which occurs with a half-time of 3 min at 
25°C and pH 7.0. tr~ns-Stimulation of D-[Inc]glucose 
exodus was not observed when 50 mM o-glucose was 
present in the extralysosomal buffer. 
V. Lysosomal nucleoside transport 
For many years, lysosomes have been known to 
contain enzymatic activities capable of degrading nu- 
cleic acids completely to nucleosides and inorganic 
phosphate, although further degradation of nucleo- 
sides to their free base and sugar has not been ob- 
served [88-93]. Several studies indicate that one of the 
major applications of these lysosomal enzymatic activi- 
ties is in degradation of cytoplasmic RNA. In 1981, 
Sameshima et al. [94] found that in Wl-38 fibroblasts, a 
pathway of RNA turnover is activated during serum 
deprivation which is inhibited by the lysosomotropic 
amine, NH4CI. Subsequently, Lardeux and Mortimore 
demonstrated that in perfused rat liver, under condi- 
tions of nutritional deprivation, 65% of total cytoplas- 
mic RNA is degraded per day, with the autophagolyso- 
somal pathway accounting for 70-85% of this 
catabolism [95]. Similar to endogenous protein break- 
down, cytoplasmic RNA degradation is subject to regu- 
lation by insulin and the intracellular concentration of 
various amino acids, showing a close correspondence 
between the fractional turnover of protein and RNA 
over the range of amino acid deprivation. Furthermore, 
the lysosomotropic amine, chloroquine, inhibits RNA 
turnover in perfused rat liver by 70%. Thus, lysosovaes 
appear to play a major role in cytoplasmic RNA 
turnover, leading to the production of large quantities 
of nucleosides within this compartment. Recently, a 
lysosomal nucleoside transport system has been charac- 
terized that provides a major route for the lysosomal 
passage of nueleosides across the lysosomal membrane 
[15]. In this investigation, adenosine uptake by human 
fibroblast lysosomes was found to be a saturable pro- 
cess, displaying a K m of 9 mM at pH 7.0 and 37 ° C. 
This K m of 9 mM for lysosomal adenosine uptake is 
25-100-times larger than that reported for adenosine 
transport across the plasma membrane of many types 
of eukaryotic cells [96-99]. The Vma x of lysosomal 
adenosine uptake, 21 pmol min-~ hex-~, is several-fold 
greater than that for any of the fibroblast lysosomal 
amino acid transport systems, making it one of the 
major carriers in the lysosomal membrane in terms of 
net transport capacity. The large Vm~ of the lysosomal 
nucleoside transport system coupled with its large K m 
enables this transport system to efficiently deal with 
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high intralysosomal concentrations of nucleosides which 
easily could be generated during degradation of nucleic 
acids within the relatively small volume of the lysoso- 
mal compartment. 
Lysosomal adenosine uptake is insensitive to pH 
over the range from pH 5-8, is not affected by the 
addition of 2 mM MgATP to incubation mixtures and 
displays an activation energy of 12.9 kCal/moi (Q~0 = 
2.0). Analog inhibition analysis revealed that this trans- 
port system recognizes both purine and pyrimidine 
nucleosides. The purine nucleosides, 2'-deoxyadeno- 
sine, inosine, 6-dimethylaminopur~ne riboside and 
purine riboside competitively inhibit lysosomal adeno- 
sine uptake, displaying Ki's ranging from 4-26 mM, 
whereas the pyrimidine nucleosides, cytidine, uridine, 
thymidine and cytosine-/3-D-arabinoside are recognized 
with lower affinity with Ki's of 23-42 mM. Nucleotides 
are not accepted by the nueleoside carrier as demon- 
strated by the lack of competitive inhibition by 5'-ADP, 
5'-AMP and 3'-AMP. Two features of the pattern of 
analog inhibition suggest that recognition is directed 
primarily towards the base portion of the nucleoside: 
(i) changing the nature of the nucleoside sugar from 
ribose to deoxyribose or arabinose has little effect on 
recognition of nucleosides by the transporter (ii) the 
sugar, o-ribose, is a very poor competitive inhibitor of 
lysosomal adenosine uptake, in contrast to the nude- 
obase, 6-dimethylaminopurine (K i = 11 mM)which is 
recognized nearly as well as adenosine and approx, half 
as well as its nucleoside, 6-dimethylaminopurine ribo- 
side (K i -- 4.4 mM). 
Addition of hydrophobic substituents at the 6 posi- 
tion of the purine ring enhances recognition by the 
nucleoside transporter. "lSrl~s is especially apparent with 
the nucleoside analeg, nitrobenzylthioinosine. Dipyri- 
damole and nitrobenzylthioinosine are extremely po- 
tent inhibitors ( K  i approx. 1 riM) of nueleoside trans- 
port across the plasma membrane of many types of 
eukaryotic ceils [96-99]. Lysosomal adenosine uptake 
is inhibited 50% by 25 /~M dipyridamole or 27 #M 
nitrobenzylthioinosine. This level of inhibition suggests 
that the lysosomal nucleoside carrier recognizes dipyri- 
damole and nitrobenzylthioinosine with 103-104-fold 
greater affinity than adenosine. 
Efflux experiments demonstrated that nucleosides 
are transported relatively quickly out of human fibro- 
blast lysosomes. The half-time of uridine and inosine 
exodus from fibroblast lysosomes was 6 rain + 0.9 and 
7.5 min + 1.0, respectively, at 37 ° C and pH 7.0 (Fig. 
12). trans-Stimulation of [3H]uridine or [3H]inesine 
exodus was not observed when saturating levels of 
inosine or uridine were added to the buffer in which 
lysosomes were suspended. Experiments involved in 
loading [all]adenosine into human fibroblast lysosomes 
revealed that adenosine is quickly deaminated to ino- 
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Fig, 12. Exodus of uridine from human fibroblast lysosomes. Fibrob- 
last lysosomes were pre-loaded by incubation with 180 mM 
13H]uridine for 20 min at pH 7.0 and 37°C. Lysosomes were then 
washed of unaccumulated radioactivity by centrifugation at 4°C, 
resuspended in pH 7.0 buffer and incubated at 37°C. At the 
indicated time points, lysosomes were collected on glass fiber filters, 
washed and counted for radioactivity [15]. 
adenosine uptake, 85% of the [3H]adenosine taken up 
by fibroblast lysosomes was recovered as adenosine 
within lysosomes but after a 15-20 min incubation 
nearly all of the radioactivity contained within the 
lysosomes was in the form of inosine. Recently, the 
enzyme responsible for this deamination of adenosine 
within lysosomes has been characterized and was found 
to be very similar to the well-characterized adenosine 
deaminas¢ from human fibroblasts and human lympho- 
cytes which is deficient in adenosine deaminase deft- 
cioncy [100]. Questions still remain as to how adeno- 
sine deaminase activity is delivered to fibroblast lyso- 
somes, what its half-life is in this compartment and 
what specific role deamination of lysosomal adenosine 
has in overall cellular metabolism. 
Lysosomal passage of nucleobases has been investi- 
gated only briefly [15]. [3H]Adenine was found to enter 
human fibroblast lysosomes by a route not saturable 
either by high concentrations of various nucleosides or 
by adenine itself. This non-saturable passage of ade- 
nine across the lysosomal membrane is distinct from 
the carrier-mediated, saturable route serving for lyso- 
somal nucleoside transport. 
Vi. Inorganic ion transport systems 
VIA. The lysosomal proton pump 
The most prominent of the lysosomal ion trans- 
porters is the lysosomal proton pump or proton 
translocating ATPase which utilizes the energy from 
ATP hydrolysis to pump protons into the lysosomal 
interior and generate an acidic intralysosomal environ- 
ment [101-106]. The lysosomal H+oATPase is electro- 
genic and displays maximal ATPase activity at pH 6.8 
and [MgATP] > 1 mM [107,108]. The lysosomal proton 
pump is similar to other vacuolar type H +-ATPases by 
its characteristic response to several inhibitors. Lysoso- 
mal acidification is insensitive to oligomycin, azide, 
cuabain, or vanadate but is strongly inhibited by N- 
ethylmaleimide and nitrate [102,107]. In contrast, the 
mitochondrial FoFI ATPases are strongly inhibited by 
oligomycin or azide and E1E2-phosphoenzyme AT- 
Pases of the plasma membrane are inhibited by vana- 
date. Vacuolar ATPases have been found in mem- 
branes of various intracellular acidic compartments in 
eukaryotic cells, chromaffin granules, coated vesicles, 
the Golgi apparatus, plant and yeast vacuoles and 
proton-transporting microsomal vesicles [109-114]. Pu- 
rification of several of the vacuolar proton pumps 
indicates that they are organized as a large complex 
often composed of at least nine different subunits 
[112,115,116]. Although structural studies of the lysoso- 
mal H+-ATPase have not yet disclosed its quaternary 
structure, several reports suggest that its subunit com- 
position is very similar to vacuolar proton pumps puri- 
fied from other membranes. Vacuolar H+-ATPases 
undergo an irreversible inhibition when exposed to 
MgATP and KNO 3 at 0 -4°C [117]. These conditions 
result in the release of a water-soluble moiety of the 
H+-ATPase from the membrane. Five polypeptides 
having apparent molecular masses of 72, 57, 41, 34 and 
33 kDa on SDS-PAGE are released from chromaffin 
granules under these conditions. Moriyama and Nelson 
found that lysosomal membranes from rat liver or rat 
kidney cortex release the same pattern of polypeptides 
when incubated with MgATP and KNO3 at 0 °C [117]. 
Antibodies against the vacuolar H+-ATPase of chro- 
maffin granules or human gastric mucosa also cross 
react with the lysosomal H+-ATPase indicating shared 
epitopes [117-119] and have allowed for the immune- 
precipitation of lysosomal polypeptides of 70, 56 and 
31 kDa [120]. Hopefully, future studies will be able to 
elucidate the role of the different subunits in the 
function and regulation of the lysosomal H+-ATPase 
and determine how its activity is related to other 
pathways of l~osomal ion conductance. 
FI-B. Lysosomal transport of sulfate and molybdate 
The investigation of sulfate transport by rat liver 
lysosomes provides a good example of the importance 
of incorporating several different approaches of analy- 
sis in studying a transport process. Jonas and Jobe 
were unable to observe any appreciable uptake of 100 
/zM [3ss]Na2SO4 by intact rat liver lysosomes during a 
20 min incubation period at 25°C and pH 7.0. In 
contrast, saturable uptake of 100 p.M [35S]Na2S.O4 was 
readily demonstrated when uptakes were performed 
with rat liver lysosomal membrane vesicles having an 
internal pH of 7.0 [18]. Sulfate uptake was 2-fold faster 
in the presence of a proton gradient (pH 5.0ou t > pH 
7.0~.) than in the absence of a gradient (pH 7.0~n = pH 
7.0ou t) and displayed a Km of 160/xM. 
Uptake of laSS]sulfate by lysosomal vesicles is 
transstimulated 5-20-fold when vesicles are pre-loaded 
with 10 mM Na2SO 4 at pH 7.0 in the absence of a 
proton gradient. NaMoO4 also strongly transstimulates 
[aSS]sulfate uptake under these conditions indicating 
that molybdate is transported by this carrier. The 
specificity of this transport system for sulfate and 
molybdate is demonstrated by the failure of 10 mM 
sodium phosphate, sodium chloride, sodium bicarbon- 
ate and sodium metabisulfite to transstimulate 
[35S]sulfate uptake to any significant degree. However, 
sulfate uptake by rat liver lysosomal membrane vesicles 
is strongly inhibited by 0.1 mM DIDS and 1 mM 
NAP-taurine which also strongly inhibit the band 3 
anion transporter. Although 10 mM chloride ion does 
not transstimulate sulfate uptake, it causes approx. 
50% c/s inhibition of sulfate uptake. At the present 
time it is not established whether this inhibitory effect 
of Cl- is due to Cl-  directly binding to the transport 
protein or is an indirect effect, such as causing a 
change in membrane potential via a chloride coaduc 
tance channel which then affects sulfate transport ac- 
tivity. 
Sulfate uptake by vesicles is not observed at pH 5.0 
in the absence of a proton gradient (pH 5.0o. t = pH 
5o0~.,.). Furthermore, agents that alter the membrane 
potential across the lysosomal vesicular membrane pro- 
duce substantial changes in sulfate uptake. Thus, the 
lysosomal sulfate/molybdate carrier appears to be reg- 
ulated, in part, by the membrane potential across the 
lysosomal membrane and possibly by different states of 
protonation. Rome and Hill have shown that sulfate is 
rapidly released from human fibroblast lysosomes fol- 
lowing lysosomal degradation of [35S]glycosaminogly- 
cans [81]. In contrast to N-acetylhexosamines, however, 
sulfate released from lysosomes rapidly exchanges with 
sulfate in the culture medium resulting in little or no 
detectable re-incorporation of this released sulfate into 
newly synthesized macromolecules. Although the ma- 
jority of sulfate released from lysosomes does not ap- 
pear to be immediately salvaged for biosynthetic pro- 
cesses, it will be interesting to determine the fate of 
molybdate released within lysosomes following degra- 
dation of molybdate-containing metailoenzymes. 
VI-C Lysosomal phosphate transport 
Recently, a phosphate transport system has been 
described in lysosomes from human fibroblasts [121]. 
Phosphate uptake by fibroblast lysosomes exhibits sat- 
urable, Michael;s-Menten kinetics with a K m of 5/~M 
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at pH 7.0 and 37 ° C. Lineweaver-Burk and V / S  vs. V 
plots are linear suggesting that phosphate uptake is 
mediated by one transport route. High specificity for 
phosphate is indicated since high concentrations of 
Na2SO 4, NaHCO a, NaCl, KCI, 3'-AMP, 5'-AMP and 
the band 3 anion transport inhibitor, 4,4'-diiso- 
thiocyanatostilbene-2,2'-disulfonate (DIDS) have no 
effect on lysosomal phosphate uptake. In contrast, the 
phosphate analog, arsenate, is a strong competitive 
inhibitor of lysosomal phosphate uptake displaying a 
K i of 7 /~M. In addition, several compounds were 
found to inhibit lysosomal phosphate uptake in a non- 
competitive manner. These were glucose-6-phosphate 
( K  i = 210 ttM), pyridoxal phosphate (K i = 250 /xM), 
C T P  ( K  i -- 140 / . tM)  and the non-hydrolyzable analog 
of ATP, AMP-PNP (K i = 80 /zM) This non-competi- 
tive inhibition suggests the existence of a site(s) distinct 
from the transport protein receptor site to which nu-. 
cleotides, glucose-6-phosphate and pyridoxal phos- 
phate can bind resulting in inhibition of lysosomal 
phosphate uptake. This site may reside on the trans- 
port protein or on a neighboring subunit if the phos- 
phate transport activity exists as a complex with other 
proteins. 
Lysosomal phosphate uptake is highly pH-depen- 
dent showing maximal uptake in the acidic pH range 
between pH 4.5 and 5.5, with half-maximal uptake 
occurring near pH 7.1 and no phosphate uptake ob- 
served at pH values > 8.5 (Fig. 13). This pH depen- 
dence of lysosomal phosphate uptake closely resembles 
the titration curve for the conversion of the monobasic 
form of phosphate to its dibasic form which has a 
pKa =7,! ,  suggesting that the lysosomal phosphate 
transport route specifically rec~.gnizes the monobasic 
form of phosphate. 
The majority of [a2p]phosphate taken up by human 
fibroblast lysosomes is rapidly converted to TCA-solu-. 
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Fig. 13. pH dependence of 0.04 mM [32p]phosphate uptake by 
human fibroblast lysosomes [121]. 
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unable to egress from fibroblast lysosomes. After a 1 
min [32P]phosphate uptake approx. 50% of the ra- 
dioactivity recovered from lysosomes is inorganic phos- 
phate and after incubations of 2.5-17 rain only 22-27% 
of the radioactivity exists as inorganic phosphate. The 
nature of the TCA-soluble products formed within 
fibroblast lysosomes is not known at the present time. 
However, we have found the TCA-insoluble material 
to consist of long chains of inorganic polyphosphate 
ranging in size from 100-600 phosphate residues in 
length (E.R. Lindley and R.L. Pisoni, J. Biol. Chem., in 
press). It is noteworthy that large amounts of polyphos- 
phate are present in yeast vacuoles which are function- 
ally analogous to lysosomes of mammalian cells 
[122,123]. 
The K m and pH dependence of the iysosomal phos- 
phate transport system differs significantly from phos- 
phate transport systems of mitochondria which display 
a g,~ near 2 mM [124,125]. In addition, phosphate 
uptake by human fibroblast lysosomes also may differ 
substantially from that in rat liver iysosomes. Schneider 
has demonstrated [32p]phosphate uptake by rat liver 
lysosomal vesicles prepared from tritosomes [126]. Both 
characteristics reported for [32p]phosphate uptake by 
rat liver lysosomai vesicles are contrary to those found 
with phosphate uptake by human fibroblast lysosomes: 
(a) 0.03 mM DIDS causes approx. 80% inhibition of 
phosphate uptake by rat liver lysosomal vesicles, 
whereas phosphate uptake by human fibroblast lyso- 
somes is not affected by [DIDS] < 0.3 mM, (b) 4.8 mM 
MgATP stimulates [32P]phosphate uptake by rat liver 
lysosomal vesicles; in contrast, 2 mM MgATP strongly 
inhibits [32P]phosphate uptake by human fibroblast 
lysosomes. Some of these differences may reflect inher- 
ent differences between isolated intact lysosomes and 
tritosomes. Ohkuma et al. [102] have noted that the 
H+-ATPase activity of isolated, intact rat liver lyso- 
somes is not inhibited by DCCD or azide, whereas 
H+-ATPase activity from rat liver tritosomes is highly 
sensitive to these two inhibitors. Hopefully, future in- 
vestigations will help to elaborate the similarities and 
differences in lysosomal phosphate transport in differ- 
ent mammalian cell types. 
Lysosomes appear to play a major role in cytoplas- 
mic RNA turnover which would generate large quanti- 
ties of inorganic phosphate within the lysosomal com- 
partment. The phosphate uptake studies using intact 
fibroblast lysosomes clearly demonstrate the presence 
of a phosphate transport system in human fibroblast 
lysosomes but the role of this transport system in 
mediating the release of large quantities of inorganic 
phosphate from lysosomes is difficult to ascertain be- 
cause of the large degree of intralysosomal phosphate 
metabolism. The possibility remains that a different 
route may serve for phosphate release from fibroblast 
lysosomes. Similar to lysosomal sulfate transport, a 
lysosomal phosphate transport system serving mainly 
for exodus may exist in human fibroblast iysosomes 
which is not detectable in s~'adies of phosphate uptake 
using intact lysosomes but may become apparent using 
lysosomal membrane vesicles. 
Lysosomes contain a membrane-bound ATPase 
which provides energy from the hydrolysis of ATP for 
operation of the lysosomal proton pump. When fibro- 
blast lysosomes are incubated with radiolabeiled ATP, 
radioactivity from [T-32p]ATP is taken up by fibroblast 
lysosomes, whereas radioactivity is not accumulated 
when lysosomes are exposed to [a-32p]ATP. These 
results indicate ~hat fibroblast lysosomes use the lyso- 
somal phosphate transport system to take up the T- 
phosphate released by hydrolysis of ATP, but ATP 
itself is not taken up. Thus, the activity of the lysoso- 
real membrane ATPase is related to the operation of 
two different lysosomal ion transport routes: the pro- 
ton pump and the phosphate transport system. 
VII. Vitamin B!2 transport and methylmalonic aciduria 
Vitamin B12 (cobalamin) is a required co-factor for a 
number of mammalian enzymes. It is known to circu- 
late in plasma bound to the protein transcobalamin I1. 
Following endoc~tosis and lysosomal degradation, 
cobalamin is released from lysosomes into the cytosol 
where the holo-en~mes are synthesized [127]. In 1985, 
Rosenblatt et al. described a defect in the release of 
cobalamin from lysosomes of an individual exhibiting a 
new form of methymalonic aciduria [128]. They demon- 
strated that fibroblasts from this patient showed in- 
creased stores of 57Co in lysosomes after exposure to 
[STCo]cobalamin for 24 h. The fraction of cobalamin 
released into the cytosol was only one-tenth that found 
in control lysosomes isolated from normal fibroblasts, 
which led Rosenblatt et al to suggest that the lysosomal 
accumulation of cobalamin was due to a defect in 
lysosomal transport of cobalamin. Complementation 
analysis using fibroblasts from the patient described 
above and fibroblasts from patients with methylmalonic 
aciduria due to other defects showed that complemen- 
tation occurred between all previously known methyl- 
malonic aciduria mutations and cells with lysosoraal 
cobalamin storage. The authors named this new defect 
involving lysosomal storage of free cobalamin, cblF 
[129]. 
Recently, it has been reported that rat liver lysoso- 
mal vesicles display a specific transport system for 
cobalamin. This system exhibits saturation kinetics with 
a K m of 3.5/~M which was demonstrable after vesicles 
had been previously loaded with 100/~M BI2. Uptake 
specificity studies demonstrated that adenosylcobal- 
amin, methylcobalamin and cobinamide dic~anide all 
competed for uptake of [57C0]B12 [130]. 
VIII. Lysosoma! di@eptide transport 
Two reports suggest the existence of dipeptide 
transport systems in lysosomal membranes. Mego has 
demonstrated that when exogenous eysteinyl-glycine is 
added to intact mouse kidney lysosomes pre-loaded 
with bovine serum albumin, the bovine serum albumin 
is degraded at an accelerated rate within the lysosomes 
presumably due to the ability of thiol to dissociate 
protein disulfide bridges thereby accelerating prote- 
olytie degradation [131]. These results imply that the 
dipeptide, cysteinyl-glyeine, is able to pass across the 
lysosomal membrane. Recently, Bird and Lloyd em- 
ployed osmotic protection studies with rat liver lyso- 
somes and found for seven pairs of dipeptide stereoiso- 
m~rs, the osmotic protection afforded by the o-stereo- 
isomers was much better than protection provided by 
the L-stereoisomers [132]. These results suggest the 
existence of a transport mechanism in rat liver lyso- 
somes which preferentially mediates lysosomal passage 
of the L-stereoisomer of some dipeptides. Of the seven 
pairs of dipeptides which were tested, loss of latency 
was rapid when lysosomes were exposed to 0.25 M 
L-AIa-L-AIa, L-AIa-GIy, or Gly-Gly, intermediate for 
GIy-L-AIa, Gly-L-Thr, and Gly-L-Ser and slow when ex- 
posed to Gly-L-Asn, GIy-L-Val or the t)-stereoisomer of 
any of the above dipeptides. 
IX. Acetyl coenzyme A: a-glucosaminide N-acetyitrans- 
ferase 
Rome and colleagues have described a lysosomal 
membrane enzyme, acetyl CoA: a-glucosaminide N- 
acetyltransferase, which catalyzes the transmembrane 
transfer of acetyi groups from cytosolic acetyl CoA to 
terminal a-linked g!ucosamine residues of heparan sul- 
fate located within the lysosomal compartment 
[133,134]. This transferase has a broad pH optimum 
from pH 6-8 and displays K~n values of 0.55 mM and 
0.3 mM for acetyl CoA and glucosamine, respectively, 
at pH 5.8 and 37 ° C. The kinetic analysis suggests that 
this enzyme works by a Di Iso Ping Pong Bi Bi mecha- 
nism. The proposed reaction cycle begins with acetyl- 
CoA binding to the enzyme on the cytoplasmic side of 
the lysosomal membrane; in the second step the en- 
zyme ~s acetylated, followed by release of CoA; the 
acetylated enzyme then undergoes a conformational 
change resulting in transmembrane relocation of the 
bound acetyl moiety towards the lysosomal ir, terior; the 
second substrate, a glucosamine residue on heparan 
sulfate, then binds to a separate site on the enzyme, 
becomes acetylated and the product released. The 
sulfhydryl reactive agent, p-chloromercuribenzoate at a 
concentration of 0.5 mM completely inhibits enzymatic 
activity, whereas 1 mM N-ethylmaleimide or 10 mM 
iodoacetamide have little effect. Heriditary deficiency 
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of acetyl CoA : a-glucosaminide N-acetyltransferase, 
known as Sanfilippo C syndrome, results in lysosomal 
accumulation of heparan sulfate because of the inabil- 
ity to degrade this mucopolysaccharide completely 
when glucosamine residues are not acetylated. 
X. Concluding remarks 
The lysosomal transport systems described in this 
review provide a firm base of knowledge for future 
investigations. Many new lysosomal transport systems 
are likely to be discovered in the future, yet there 
remain many interesting areas of inquiry invol,,ing the 
currently known lysosomal carriers. During these inves- 
tigations, much has been learned beyond understand- 
ing the characteristics of individual transport systems. 
The basis of four different genetic disorders in lysoso- 
mal transport is now known and the techniques that 
have been developed greatly enhance the ability to 
characterize other lysosomal transport disorders. An 
understanding of the mechanism of cysteamine therapy 
of cystinosis has been obtained, allowing for discovery 
of other agents capable of depleting cystinotic cells of 
their accumulated cystine. Unexpected intralysosomal 
metabolism of adenosine and phosphate have pointed 
to the occurrence of lysosomal en~matic activities 
previously not known. Hormonal regulation of lysoso- 
mal system h has demonstrated modulation of a spe- 
cific lysosomal transport system to meet the metabolic 
needs of a specialized tissue. The properties of the 
Iysosomal nucleoside transport system demonstrates 
the ability of lysosomes to deal effectively with the 
degradation of nucleic acids and to recycle their key 
metabolic components. In addition, the cysteine- 
specific lysosomal transport route delivers large quanti- 
ties of cysteine into lysosomes, suggesting a role for 
this thiol in lysosomal metabolic activities. 
Several photoaffinity probes and chemical modifying 
agents now have been identified which may be useful 
for specifically labelling some lysosomal transport pro- 
teins. Furthermore, the cystine dimethyl ester selection 
technique may aid identification of the lysosomal cys- 
tine transport gene. Efforts in these areas will ulti- 
mately lead to an understanding of the structure of the 
lysosomal transport proteins, the factors that affect 
their function within the lysosomal membrane and the 
way these carriers are targeted to lysosomes. Knowl- 
edge of the lysosomal transport systems also will be 
crucial for developing drug delivery strategies in which 
agents are specifically delivered to lysosomes by recep- 
tor-mediated endocytosis. H~ving developed the tools 
for investigation and a strong base of knowledge, one 
eagerly anticipates further advances in understanding 
the role of transport systems in lysosomal function and 
their contribution to health and disease. 
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